Patents by Inventor Vered Behar

Vered Behar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF HEXOKINASE 2/MITOCHONDRIA-DETACHING COMPOUNDS FOR TREATING HEXOKINASE-2 (HK2)-EXPRESSING CANCERS
    Publication number: 20260102386
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for treating, inhibiting, or suppressing a hexokinase-2 (HK2)-expressing cancer.
    Type: Application
    Filed: December 15, 2025
    Publication date: April 16, 2026
    Applicant: Vidac Pharma Ltd.
    Inventors: Vered BEHAR, Oren Menahem BECKER, Hadas Tamar PAHIMA, Reut YOSEF HAMO
  • Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers
    Patent number: 12527782
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for treating, inhibiting, or suppressing a hexokinase-2 (HK2)-expressing cancer.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: January 20, 2026
    Assignee: Vidac Pharma Ltd.
    Inventors: Vered Behar, Oren Menahem Becker, Hadas Tamar Pahima, Reut Yosef Hamo
  • Piperazine derivatives, pharmaceutical compositions and methods of use thereof
    Patent number: 12162868
    Abstract: The present invention relates to novel piperazine derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially for targeted therapy treatment of hyperproliferative disorders, including benign hyperproliferative disorders, cancer and pre-cancer conditions.
    Type: Grant
    Filed: August 8, 2021
    Date of Patent: December 10, 2024
    Assignee: Vidac Pharma Ltd..
    Inventors: Paul Salama, Vered Behar, Oren Menahem Becker
  • Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses
    Patent number: 12083111
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for inducing immune responses in a subject, including potentiating the immune response to hyperproliferative disorders such as cancer and potentiating the immune response to infectious diseases.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: September 10, 2024
    Assignee: Vidac Pharma Ltd ..
    Inventors: Vered Behar, Oren Menahem Becker, Reut Yosef Hamo, Eyal Dor-On
  • USE OF HEXOKINASE 2/MITOCHONDRIA-DETACHING COMPOUNDS FOR TREATING HEXOKINASE-2 (HK2)-EXPRESSING CANCERS
    Publication number: 20220143004
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for treating, inhibiting, or suppressing a hexokinase-2 (HK2)-expressing cancer.
    Type: Application
    Filed: January 25, 2022
    Publication date: May 12, 2022
    Applicant: Vidac Pharma Ltd.
    Inventors: Vered BEHAR, Oren Menahem BECKER, Hadas Tamar PAHIMA, Reut YOSEF HAMO
  • PIPERAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220098179
    Abstract: The present invention relates to novel piperazine derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially for targeted therapy treatment of hyperproliferative disorders, including benign hyperproliferative disorders, cancer and pre-cancer conditions.
    Type: Application
    Filed: August 8, 2021
    Publication date: March 31, 2022
    Applicant: Vidac Pharma Ltd.
    Inventors: Paul Salama, Vered Behar, Oren Menahem Becker
  • Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers
    Patent number: 11266639
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for treating, inhibiting, or suppressing a hexokinase-2 (HK2)-expressing cancer.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 8, 2022
    Assignee: VIDAC PHARMA LTD.
    Inventors: Vered Behar, Oren Menahem Becker, Hadas Tamar Pahima, Reut Yosef Hamo
  • USE OF HEXOKINASE 2/MITOCHONDRIA-DETACHING COMPOUNDS FOR ACTIVATING IMMUNE RESPONSES
    Publication number: 20210369697
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for inducing immune responses in a subject, including potentiating the immune response to hyperproliferative disorders such as cancer and potentiating the immune response to infectious diseases.
    Type: Application
    Filed: August 17, 2021
    Publication date: December 2, 2021
    Applicant: Vidac Pharma Ltd.
    Inventors: Vered BEHAR, Oren Menahem BECKER, Reut YOSEF HAMO, Eyal DOR-ON
  • Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses
    Patent number: 11096935
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for inducing immune responses in a subject, including potentiating the immune response to hyperproliferative disorders such as cancer and potentiating the immune response to infectious diseases.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: August 24, 2021
    Assignee: VIDAC PHARMA LTD
    Inventors: Vered Behar, Oren Menahem Becker, Reut Yosef Hamo, Eyal Dor-On
  • Piperazine derivatives, pharmaceutical compositions and methods of use thereof
    Patent number: 11084807
    Abstract: The present invention relates to novel piperazine derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially for targeted therapy treatment of hyperproliferative disorders, including benign hyperproliferative disorders, cancer and pre-cancer conditions.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: August 10, 2021
    Assignee: VIDAC PHARAMA LTD.
    Inventors: Paul Salama, Vered Behar, Oren Menahem Becker
  • USE OF HEXOKINASE 2/MITOCHONDRIA-DETACHING COMPOUNDS FOR ACTIVATING IMMUNE RESPONSES
    Publication number: 20200188381
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for inducing immune responses in a subject, including potentiating the immune response to hyperproliferative disorders such as cancer and potentiating the immune response to infectious diseases.
    Type: Application
    Filed: January 29, 2020
    Publication date: June 18, 2020
    Applicant: Vidac Pharma Ltd.
    Inventors: Vered BEHAR, Oren Menahem BECKER, Reut YOSEF HAMO, Eyal DOR-ON
  • Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses
    Patent number: 10682346
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for inducing immune responses in a subject, including potentiating the immune response to hyperproliferative disorders such as cancer and potentiating the immune response to infectious diseases.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: June 16, 2020
    Assignee: VIDAC PHARMA LTD.
    Inventors: Vered Behar, Oren Menahem Becker, Reut Yosef Hamo, Eyal Dor-On
  • PIPERAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200031815
    Abstract: The present invention relates to novel piperazine derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially for targeted therapy treatment of hyperproliferative disorders, including benign hyperproliferative disorders, cancer and pre-cancer conditions.
    Type: Application
    Filed: August 17, 2017
    Publication date: January 30, 2020
    Inventors: Paul SALAMA, Oren Menahem BECKER, Vered BEHAR
  • USE OF HEXOKINASE 2/MITOCHONDRIA-DETACHING COMPOUNDS FOR ACTIVATING IMMUNE RESPONSES
    Publication number: 20180303819
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for inducing immune responses in a subject, including potentiating the immune response to hyperproliferative disorders such as cancer and potentiating the immune response to infectious diseases.
    Type: Application
    Filed: November 7, 2017
    Publication date: October 25, 2018
    Applicant: Vidac Pharma Ltd.
    Inventors: Vered BEHAR, Oren Menahem BECKER, Reut YOSEF HAMO, Eyal DOR-ON
  • USE OF HEXOKINASE 2/MITOCHONDRIA-DETACHING COMPOUNDS FOR TREATING HEXOKINASE-2 (HK2)-EXPRESSING CANCERS
    Publication number: 20180303820
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for treating, inhibiting, or suppressing a hexokinase-2 (HK2)-expressing cancer.
    Type: Application
    Filed: November 7, 2017
    Publication date: October 25, 2018
    Applicant: Vidac Pharma Ltd.
    Inventors: Vered BEHAR, Oren Menahem BECKER, Hadas Tamar PAHIMA, Reut YOSEF HAMO
  • Compositions and methods for modulating a kinase
    Patent number: 8937065
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase signaling cascade.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: January 20, 2015
    Assignee: Clevexel Pharma
    Inventors: Oren M. Becker, Itai Bloch, Efrat Ben-Zeev, Alina Shitrit, Avihai Yacovan, Sharon Gazal, Vered Behar, Alexander Konson, Nili Schutz, Sima Mirilashvili, Gali Golan
  • Sulfonamides for the modulation of PKM2
    Patent number: 8692001
    Abstract: The invention relates to sulfonamide compounds and methods for activating PKM2. The compounds and methods are useful in treating or preventing a disease or disorder selected from cancer, cell proliferative disorder, inflammatory disorder, metabolic disorder, and immune system disorder.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: April 8, 2014
    Assignee: Dynamix Pharmaceuticals Ltd.
    Inventors: Oren M. Becker, Alina Shitrit, Nili Schutz, Efrat Ben-Zeev, Avihai Yacovan, Rachel Ozeri, Tzofit Kehat, Sima Mirilashvili, Alex Aizikovich, Daniel Sherman, Vered Behar, Osnat Kashtan
  • Compositions and Methods for Modulating a Kinase
    Publication number: 20120316148
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase signaling cascade.
    Type: Application
    Filed: June 7, 2012
    Publication date: December 13, 2012
    Applicant: Dynamix Pharmaceuticals LTD.
    Inventors: Oren M. Becker, Itai Bloch, Efrat Ben-Zeev, Alina Shitrit, Avihai Yacovan, Sharon Gazal, Vered Behar, Alexander Konson, Nili Schutz, Sima Mirilashvili, Gali Golan
  • Pyrazolines for the Modulation of PKM2
    Publication number: 20120302609
    Abstract: The invention relates to pyrazoline substituted compounds and methods for activating PKM2. The compounds and methods are useful in treating or preventing a disease or disorder selected from cancer, cell proliferative disorder, inflammatory disorder, metabolic disorder, and immune system disorder.
    Type: Application
    Filed: May 23, 2012
    Publication date: November 29, 2012
    Applicant: Dynamix Pharmaceuticals LTD.
    Inventors: Oren M. Becker, Alina Shitrit, Nili Schutz, Efrat Ben-Zeev, Avihai Yacovan, Rachel Ozeri, Daniel Sherman, Vered Behar, Osnat Kashtan, Alexander Konson
  • Sulfonamides for the Modulation of PKM2
    Publication number: 20120108631
    Abstract: The invention relates to sulfonamide compounds and methods for activating PKM2. The compounds and methods are useful in treating or preventing a disease or disorder selected from cancer, cell proliferative disorder, inflammatory disorder, metabolic disorder, and immune system disorder.
    Type: Application
    Filed: October 26, 2011
    Publication date: May 3, 2012
    Inventors: Oren M. Becker, Alina Shitrit, Nili Schutz, Efrat Ben-Zeev, Avihai Yacovan, Rachel Ozeri, Tzofit Kehat, Sima Mirilashvili, Alex Aizikovich, Daniel Sherman, Vered Behar, Osnat Kashtan